Among these, PARP inhibitors have demonstrated efficacy, particularly for BRCA-related, high-grade ovarian cancer, BRCA-mutated breast cancer as well as triple negative breast cancer (TNBC). Here, PARP1 is linked to ovarian carcinoma.